Oncolytics Biotech Inc (NASDAQ: ONCY) (TSX: ONC), a company specialising in immunotherapy for oncology, announced on Friday that it will present new data from its Phase I/II GOBLET clinical trial at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

The presentation highlights pelareorep's mechanism of action in pancreatic ductal adenocarcinoma (PDAC), offering new insights into how this immunotherapy stimulates multiple arms of the immune system and primes tumours for treatment. It will share details on how pelareorep initiates the expansion of reovirus-specific T cells that are associated with favourable clinical responses at week 24, amongst other results.